Shamburg News · 8-K filed Oct 30, 2026, 9:17 AM EDT
Pelthos Therapeutics to Combine with Castle Creek Biosciences in Merger and $57.5 Million PIPE
PTHS · Pelthos Therapeutics Inc.
- Material agreement
- Acquisition
- Financing
- Leadership change
- Shareholder vote
- Reg FD disclosure
- Other event
- Materiality: high
On October 30, 2026, Pelthos Therapeutics entered into a merger agreement with Castle Creek Biosciences, under which Castle Creek stockholders will receive 5,200,000 shares of Pelthos common stock at closing, plus contingent shares, milestone payments and a share of priority review voucher proceeds. Concurrently, Pelthos entered into a securities purchase agreement for a PIPE financing of approximately $57.5 million, with a maximum potential size of $80.0 million including bridge financing. The filing also reports an amended and restated $50.0 million venture loan facility with Horizon, an amendment to senior secured convertible notes, and a CEO severance amendment and salary increase to $550,000.
Source: SEC EDGAR, Form 8-K, Items 1.01, 2.03, 3.02, 3.03, 5.02, 5.03, 5.07, 7.01, 9.01, accession 0001104659-26-120457.
Written from the filing by Shamburg Markets. Figures are as reported by the company.